A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer

Inclusion Criteria: * 1.Fully understood the study and voluntarily signed Informed Consent Form * 2.Age \> 18 years * 3.Histologically or cytologically documented locally advanced or Metastatic pulmonary sarcomatoid carcinoma (PSC) patients and other Non-small cell lung cancer（NSCLC） with MET Exon 14 mutation who have failed piror systemic therapy(ies), or are unwilling or unable to receive chemotherapy * 4.Patient should have measurable disease per RECIST1.1 * 5.ECOG performance status of 0, or 1 * 6.Expected survival \> 12 weeks Exclusion Criteria: * 1.Co-existing malignancy or malignancies diagnosed within the last 3 years other than lung cancer with the exception of adequately treated skin basal cell carcinoma or cervical cancer in situ. * 2.Any anti-cancer therapy, including chemotherapy, hormonal therapy, biologic therapy or radiotherapy within 3weeks prior to initiation of study treatment, or received TKI (for ex. EGFR-TKI) treatment within 2 week prior to initiation of study treatment * 3.Palliative radiation to bone metastases within 2 weeks prior to the initiation of study treatment * 4.Herbal therapy within 1 week prior to the initiation of study treatment * 5\. has EGFR, ALK or ROS 1 positive mutation